Literature DB >> 22785342

West nile virus disease and other arboviral diseases - United States, 2011.

.   

Abstract

Arthropodborne viruses (arboviruses) are transmitted to humans primarily through the bites of infected mosquitoes and ticks. Symptomatic infections most often manifest as a systemic febrile illness and, less commonly, as neuroinvasive disease (e.g., meningitis, encephalitis, or acute flaccid paralysis). West Nile virus (WNV) is the leading cause of domestically acquired arboviral disease in the United States. However, several other arboviruses also cause seasonal outbreaks and sporadic cases. In 2011, CDC received reports of 871 cases of nationally notifiable arboviral diseases (excluding dengue); etiological agents included WNV (712 cases), La Crosse virus (LACV) (130), Powassan virus (POWV) (16), St. Louis encephalitis virus (SLEV) (six), Eastern equine encephalitis virus (EEEV) (four), and Jamestown Canyon virus (JCV) (three). Of these, 624 (72%) were classified as neuroinvasive disease, for a national incidence of 0.20 per 100,000 population. WNV and other arboviruses continue to cause focal outbreaks and severe illness in substantial numbers of persons in the United States.

Entities:  

Mesh:

Year:  2012        PMID: 22785342

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  20 in total

1.  Emerging infections of the central nervous system.

Authors:  Jennifer Lyons; Justin McArthur
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

2.  Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines.

Authors:  Melissa N Garcia; Anne M Hause; Christopher M Walker; Jordan S Orange; Rodrigo Hasbun; Kristy O Murray
Journal:  Viral Immunol       Date:  2014-07-25       Impact factor: 2.257

Review 3.  Innate host responses to West Nile virus: Implications for central nervous system immunopathology.

Authors:  Giada Rossini; Maria Paola Landini; Francesco Gelsomino; Vittorio Sambri; Stefania Varani
Journal:  World J Virol       Date:  2013-05-12

Review 4.  Viruses and antiviral immunity in Drosophila.

Authors:  Jie Xu; Sara Cherry
Journal:  Dev Comp Immunol       Date:  2013-05-13       Impact factor: 3.636

Review 5.  Tick-Borne Flaviviruses, with a Focus on Powassan Virus.

Authors:  Gábor Kemenesi; Krisztián Bányai
Journal:  Clin Microbiol Rev       Date:  2018-12-12       Impact factor: 26.132

Review 6.  West Nile virus infection and immunity.

Authors:  Mehul S Suthar; Michael S Diamond; Michael Gale
Journal:  Nat Rev Microbiol       Date:  2013-02       Impact factor: 60.633

7.  Lack of evidence of increased West Nile virus disease severity in the United States in 2012.

Authors:  Nicole P Lindsey; J Erin Staples; Mark J Delorey; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2013-11-11       Impact factor: 2.345

8.  Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Authors:  A Venkatesan; A R Tunkel; K C Bloch; A S Lauring; J Sejvar; A Bitnun; J-P Stahl; A Mailles; M Drebot; C E Rupprecht; J Yoder; J R Cope; M R Wilson; R J Whitley; J Sullivan; J Granerod; C Jones; K Eastwood; K N Ward; D N Durrheim; M V Solbrig; L Guo-Dong; C A Glaser
Journal:  Clin Infect Dis       Date:  2013-07-15       Impact factor: 9.079

9.  Initial and long-term costs of patients hospitalized with West Nile virus disease.

Authors:  J Erin Staples; Manjunath B Shankar; James J Sejvar; Martin I Meltzer; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2014-02-10       Impact factor: 2.345

10.  Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.

Authors:  Olga A Maximova; James M Speicher; Jeff R Skinner; Brian R Murphy; Marisa C St Claire; Danny R Ragland; Richard L Herbert; Dan R Pare; Rashida M Moore; Alexander G Pletnev
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.